Effect of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease

January 7, 2026 updated by: Hongbing Xu, Peking Union Medical College

A Randomized Crossover Trial of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease

Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients diagnosed with interstitial lung disease (ILD).
  • Stable disease status, defined as no hospitalization due to acute exacerbation within the past month.

Exclusion Criteria:

  • Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders.
  • A history of respiratory tract infection within the past two weeks.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Purifier (without Filter) Arm
Behavioral: Purifier (without Filter) Arm
Place an air purifier without a filter in the home.
Experimental: Air Purifier (with Filter) Arm
Behavioral: Air Purifier (with Filter) Arm
Place an air purifier with high-efficiency filters in the home, and turn it on for at least 18 hours every day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score)
Time Frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
St. George's Respiratory Questionnaire (SGRQ):Score Range:Minimum score: 0 points;Maximum score: 100 points.A higher score indicates worse outcomes for the patient.
Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity)
Time Frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Quality of Life Indicators (e.g., CAT Score)
Time Frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
COPD Assessment Test (CAT):It is a short, validated, patient-reported outcome (PRO) tool specifically designed to measure the impact of pulmonary disease on a patient's health status and daily life.Score Range:Minimum score: 0 points;Maximum score: 40 points.A higher score indicates worse health status and greater pulmonary disease-related burden for the patient.
Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Blood Sample Indicators (e.g., Concentration of Interleukin-8)
Time Frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Assessment of Changes in Pulmonary Inflammation or Lung Injury Before and After Intervention Using Concentrations of Biomarkers Such as Interleukin-8
Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking Union Medical College

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

December 22, 2025

First Submitted That Met QC Criteria

January 7, 2026

First Posted (Actual)

January 15, 2026

Study Record Updates

Last Update Posted (Actual)

January 15, 2026

Last Update Submitted That Met QC Criteria

January 7, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CAMS-PUMC-IRM-IAQ-ILD-2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

  1. The informed consent form signed by study participants does not include clauses authorizing the sharing of de-identified individual participant data (IPD) with external researchers. In accordance with the ethical approval requirements, no secondary use of IPD beyond the primary study objectives is permitted without explicit participant consent.
  2. The sample size of this study is relatively small, and the collected IPD has high heterogeneity due to individual differences in patient clinical characteristics and intervention responsiveness. Sharing such a limited dataset may not support robust secondary research findings, and could lead to misleading interpretations of the intervention effect on pulmonary inflammation.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ILD

Clinical Trials on Purifier (without Filter) Arm

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe